Kevin Braunscheidel

Kevin Braunscheidel is a post-doctoral researcher at Icahn School of Medicine at Mount Sinai. Dr. Braunscheidel's lab is developing novel therapeutics that target peripheral sensory systems to limit nicotine intake, bypassing the blood-brain barrier. By focusing on nicotine's actions outside the brain, they are creating new treatments that could drastically improve quit rates and reduce the financial burden on both individuals and the healthcare system. These advancements have the potential to improve the quality of life for millions struggling to quit smoking.